Tons of dark pool trades hit ARWR stock in after-hours trading on December 22, 2019, as the stock uplists to the S&P MidCap 400 effective on Monday, December 23, 2019. ARWR stock pulled back during the day which gave the whales excellent cover to pick up shares cheaper over dark pools in order to rebalance due to the S&P changes. Check out the huge wave the whales made in ARWR stock.
On December 23, 2019, the S&P Dow Jones Indices will make the following index adjustments to the S&P 500, S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market capitalization range. The changes will be effective prior to the open of trading on Monday, December 23 to coincide with the December re-balance. Arrowhead Pharmaceuticals (ARWR) will switch places with Granite Construction (GVA) in the S&P MidCap 400. Arrowhead Pharmaceuticals has a market capitalization more representative of the mid-cap market space, and Granite Construction has a market capitalization more representative of the small-cap market space.
On December 20, 2019, Arrowhead Pharmaceuticals announced that it has dosed the first patient in AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference therapeutic being developed as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead is also conducting the SEQUOIA Phase 2/3 trial, which is an ongoing potentially pivotal study that began dosing patients in August.
Javier San Martin, M.D., chief medical officer at Arrowhead, said: “We are committed to helping the alpha-1 community and would like to thank the participating investigators and patients, who currently have no available treatment options for alpha-1 liver disease other than liver transplant. AROAAT2002 is an important study within our ARO-AAT development program, which provides us with a key opportunity to assess patient response to treatment at various timepoints. This may prove to be helpful for future regulatory and commercial planning as the ARO-AAT development program progresses.”
On December 16, 2019, Arrowhead Pharmaceuticals announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-HSD, the company’s investigational RNA interference, or RNAi, therapeutic being developed as a treatment for patients with alcohol related and nonalcohol related liver diseases, such as nonalcoholic steatohepatitis, or NASH. Pending approval, Arrowhead intends to proceed with AROHSD1001, a Phase 1 single and multiple dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of ARO-HSD in normal healthy volunteers as well as in patients with NASH or suspected NASH. Additional exploratory objectives include assessment of various measures of drug activity using liver biopsy. The application for approval of the clinical trial is being submitted to a local Ethics Committee and to the New Zealand Medicines and Medical Devices Safety Authority for review by the Standing Committee on Therapeutic Trials.
Javier San Martin, M.D., chief medical officer at Arrowhead, said: “HSD17B13, a member of the hydroxysteroid dehydrogenase family involved in the metabolism of hormones, fatty acids, and bile acids, has emerged as a potentially interesting target for multiple forms of liver disease. Published human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against alcoholic hepatitis, cirrhosis, and nonalcoholic steatohepatitis, or NASH, with approximately 30-50% risk reduction compared to non-carriers. This genetic validation gives us confidence about the target gene as we embark on what we believe is the first clinical program using any modality against HSD17B13.”
On December 13, 2019, Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced that the board of directors appointed veteran pharmaceutical industry executive Marianne De Backer, Ph.D., as an independent director of the company, with a term beginning effective immediately.
Douglass Given, M.D., Ph.D., Chairman of the Board of Arrowhead, said, “Marianne is a seasoned pharmaceutical executive, with a stellar track record showing deep scientific expertise and solid commercial acumen across the globe. The perspective she brings as an executive at Bayer and Johnson & Johnson will be valuable to Arrowhead as the company continues to grow.”
“I’m excited to join the Board of Arrowhead Pharmaceuticals,” said De Backer. “I have long admired Arrowhead’s proven ability to advance science at a rapid pace toward solving genuine unmet medical needs. I look forward to helping guide the company along that path.”
Marianne De Backer is currently Executive Vice President, Head of Global Business Development & Licensing, and a member of the Executive Committee of the Pharmaceuticals Division of Bayer AG. Before joining Bayer, Dr. De Backer held a series of positions in the Johnson & Johnson family of companies. She started as a scientist and scientific group leader during which time her work resulted in multiple patents. She progressed through commercial positions internationally including leading a sales and marketing business unit responsible for several product lines, culminating as Vice President, M&A Operations, Divestitures, and Janssen Business Development. During her tenure with Johnson & Johnson, Dr. De Backer had direct accountability for over 200 strategic alliances. Dr. De Backer received a MSc in Molecular Biology from the University of Brussels, Belgium, a Masters in Engineering and Biochemistry and a Ph.D. in Biotechnology from the University of Ghent, Belgium, and an MBA from Rotterdam School of Management, Erasmus University, The Netherlands.
On December 12, 2019, Oppenheimer analyst Esther Rajavelu initiated coverage of Arrowhead with a Perform rating, saying she values the shares in a range of $60-$67. Rajavelu said that she believes the company is in the beginning phases of leveraging its platform to diversifty its pipeline and engage in commercial value creation over time. The analyst added that she likes its validated RNAi technology with potential applicability in multiple tissue types, its clinical stage pipeline with optionality to pursue large or orphan indications, and its recently funded balance sheet.